Abstracts tagged "chemokines"

Abstract Number: 272 • 2016 ACR/ARHP Annual Meeting
Interferon Chemokine Score and Other Cytokine Measures Predict Changes in Disease Activity in Patients with Juvenile and Adult Dermatomyositis
Cynthia S. Crowson¹, Jeannette M. Olazagasti Lourido², Molly S. Hein³, Richard S. Pendegraft⁴, Michael A. Strausbauch⁵, Timothy B. Niewold⁶, Floranne C. Ernste⁷, Theresa L. Wampler Muskardin³, Erik J. Peterson⁸, Emily C. Gillespie⁹ and Ann M Reed¹⁰, ¹Health Sciences Research, Mayo Clinic, Rochester, MN, ²University of Puerto Rico, San Juan, Puerto Rico, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Biomedical Statistics and informatics, Rochester, MN, ⁵Surgical Research, Mayo Clinic, Rochester, MN, ⁶Rheumatology and Immunology, Mayo Clinic, Rochester, MN, ⁷Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁸Center for Immunology/Department of Medicine, University of Minnesota, Minneapolis, MN, ⁹Medicine, University of Minnesota, Minneapolis, MN, ¹⁰Rheumatology, Duke University, Durham, NC
Background/Purpose: Methods: Multiplexed immunoassays (Meso Scale Discovery) enabled simultaneous measurement of IFN-regulated chemokines and other pro- and anti-inflammatory cytokines specific to differentiation of specific…
Abstract Number: 829 • 2016 ACR/ARHP Annual Meeting
High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts
Anna Hoffmann-Vold¹, Richard Huyen², Elizabeth R. Volkmann², Oyvind Midtvedt¹, Vyacheslav Palchevskiy², May Brit Lund³, Torhild Garen¹, Trond Mogens Aalokken⁴, Anders Heiervang Tennøe¹, Stephen Samuel Weigt², Mike Shino², Rajan Saggar⁵, David Ross², Joseph Lynch III², Thor Ueland⁶, Michael Fishbein⁷, Pål Aukrust⁸, Øyvind Molberg¹ and John A Belperio², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Research, Oslo University Hospital, Oslo, Norway, ⁷Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…
Abstract Number: 1120 • 2016 ACR/ARHP Annual Meeting
Interleukin-1β Stabilize CXCL2 mRNA and Increase Its Expression
Satoshi Yamasaki, Yusuke Yoshida and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Changes in gene expression are closely related to inflammation and joint destruction in RA. Recently, it has been recognized that post-transcriptional regulation of the…
Abstract Number: 1128 • 2016 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Inhibits Cartilage Destruction and Bone Erosion in Collagen-Induced Arthritis Model
Kana Hoshino¹, Masayoshi Ohkuro², Wataru Ikeda¹, Tomoya Nakatani¹, Yoshikazu Kuboi³, Naoto Ishii¹, Toshihiko Yamauchi¹, Nobuyuki Yasuda¹ and Toshio Imai¹, ¹KAN Research Institute Inc., Chuo-ku, Kobe-shi, Japan, ²Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki-ku, Kawasaki-shi, Japan, ³Medicine Creation. Neuro Business Group, Eisai Co., Ltd., Tsukuba-shi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease leading to joint destruction. In the previous Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN)…
Abstract Number: 1130 • 2016 ACR/ARHP Annual Meeting
Aminopeptidase N/CD13 Induces Monocyte Migration in Vitro and In Vivo and Signals through GPCR, Erk1/2, Jnk, Src, and NFκB
Yuxuan Du¹, W. Alexander Stinson², Phillip Campbell¹, Rachel Morgan¹, Nicholas Lepore¹, Ellen Cealey¹, Jonatan Hervoso¹, Huadong Cui², David Fox³ and M. Asif Amin⁴, ¹Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Aminopeptidase N/CD13 is a metalloproteinase expressed on the surface of fibroblast like synoviocytes (FLS). It is found in soluble form in serum and rheumatoid…
Abstract Number: 1318 • 2016 ACR/ARHP Annual Meeting
Profile of Macrophage-Derived Cytokines and Chemokines of Patients with Chikungunya-Induced Chronic Arthralgia/Arthritis
Idali Martinez¹, Edwin Lopez¹, Zelma L. Rios¹ and Luis M. Vilá², ¹Department of Microbiology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ²Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Chikungunya virus (CHIKV) caused a large epidemic in Puerto Rico in 2014 with more than 30,000 reported cases. Many of the affected individuals developed…
Abstract Number: 1458 • 2016 ACR/ARHP Annual Meeting
Intraadrenal Dendritic Cells Inhibit Corticosterone Response during Collagen-Induced Arthritis – a Role for IL-1β and CXC Chemokines?
Hubert Stangl, Christine Wolff, Martin Lesiak and Rainer Straub, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: In rheumatoid arthritis (RA) and collagen-induced arthritis (CIA) the phenomenon of a relative insufficiency of adrenal glands to produce an adequate amount of anti-inflammatory…
Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Hideto Akama⁵, Nobuyuki Yasuda⁵, Fumitoshi Tago⁵, Makoto Kawakubo⁵, Seiichiro Hojo⁵, Tetsu Kawano⁶ and Toshio Imai⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, ³Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵EISAI Co. Ltd., Tokyo, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 1361 • 2015 ACR/ARHP Annual Meeting
Synovial Macrophages Promote TGF-β Signaling but Protect Against Influx of S100A8/S100A9-Producing Cells after Intra-Articular Injections of Oxidized Low-Density Lipoproteins
Wouter de Munter¹, Martijn H. van den Bosch¹, Arjen Blom¹, Birgitte Walgreen², Monique Helsen¹, Leo Joosten³, Johannes Roth⁴, Thomas Vogl⁵, Fons van de Loo¹, Marije Koenders¹, Wim van den Berg¹, Peter van der Kraan¹ and Peter van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimentel Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Internal Medicine, Radboud university medical center, Nijmegen, Netherlands, ⁴Institute of Immunology, University of Münster, Münster, Germany, ⁵University of Muenster, Muenster, Germany
Background/Purpose: In previous studies we found that synovial macrophages regulate joint pathology during experimental osteoarthritis (OA). Recently, we found that high systemic levels of LDL…
Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting
Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma
Edward Stern^1,2, Cassandra Hong², Voon H. Ong², Aine Burns¹, Robert Unwin³ and Christopher P. Denton⁴, ¹Nephrology, Royal Free Hospital, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, UCL Division of Medicine, London, United Kingdom, ⁴Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom
Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…
Abstract Number: 1964 • 2015 ACR/ARHP Annual Meeting
Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis
Katja Lakota¹, Tadeja Kuret², Polona Žigon¹, Ziga Rotar¹, Matija Tomsic¹, Saša Čučnik^1,2, Snezna Sodin Semrl^1,3 and Alojzija Hocevar¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, ³Faculty of Mathematics, Natural Science and Information Technology, University of Primorska, Koper, Slovenia
Background/Purpose: Giant cell arteritis (GCA) is a large- and medium- vessel arteritis characterized by a range of histological patterns of vascular wall injury. The temporal…
Abstract Number: 2013 • 2015 ACR/ARHP Annual Meeting
TIARP Attenuates Autoantibody-Mediated Arthritis Via the Suppression of Neutrophil Infiltration into the Joint
Asuka Inoue¹, Isao Matsumoto¹, Yuki Tanaka², Naoto Umeda¹, Hoshimi Kawaguchi¹, Hiroshi Ebe¹, Yoshihiro Matsumoto³ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Internal Medicine, University of Tsukuba, Tsukuba, Japan, ³Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan
Background/Purpose: TIARP (TNFα-induced adipose-related protein) is dominantly expressed in macrophages (Mφ), neutrophils (PMN) and fibroblast-like synoviocytes (FLS). Recently, we found that TIARP functions as a…
Abstract Number: 2086 • 2015 ACR/ARHP Annual Meeting
Inhibition of Macrophage Inflammatory Protein 1-Alpha (CCL3) Significantly Reduced Bone Resorption in Vitro and the Development of Erosive Joint Pathology in Collagen-Induced Arthritis
Lauren A. Jordan¹, Ruth Davies¹, Alastair J. D. Robertson², Ann K. Harvey¹, Ernest H. Choy¹, Malin Erlandsson³, Maria I. Bokarewa⁴, Rachel J. Errington¹ and Anwen S. Williams¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²William Harvey Hospital, Willesborough, Ashford, United Kingdom, ³University of Goteborg, Goteborg, Sweden, ⁴Guldhedsgatan 10, University of Goteborg, Goteborg, Sweden
Background/Purpose: The destruction of bone is a common feature of diseases like rheumatoid arthritis (RA) and multiple myeloma (MM). CCL3 is significantly elevated in the…
Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting
CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Anastasiya Muntyanu¹, Fatima Abji², Kun Liang³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…
Abstract Number: 2993 • 2015 ACR/ARHP Annual Meeting
Serum CXCL4 Increase in Patients with Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis Is Associated with Anti-Scl70 Antibodies and ICAM-1, a Marker of Endothelial Activation
Serena Vettori¹, Rosaria Irace², Veronica Giacco², Antonella Riccardi², Lucia Vicedomini², Luciana Pellecchia² and Gabriele Valentini², ¹Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy
Background/Purpose: CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine, that has been shown to be increased in the sera of patients with systemic sclerosis (SSc)…

« Previous Page
1
…
5
6
7
8
9
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].